About: Zanamivir

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Zanamivir Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4767-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4768-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Meindl P, Bodo G, Palese P, Schulman J, Tuppy H: Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974 Apr;58(2):457-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4362431 # von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993 Jun 3;363(6428):418-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8502295 # Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T: Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases. Antimicrob Agents Chemother. 2008 Aug 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18694948 # Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K: Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008 Aug 1;47(3):339-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18582202 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	2.5-5.1 hours (en)
http://linked.open...ugbank/indication	For the prevention and treatment of influenza A and B. (en)
http://linked.open...bank/manufacturer	Amerisource Health Services Corp.
sameAs	Zanamivir Zanamivir
Title	Zanamivir (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/bindingdb/4934 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/chebi/50663 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/chemspider/54842 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/drugbank/DB00558 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/kegg-compound/C08095 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/kegg-drug/D00902 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/national-drug-code-directory/0173-0681-01 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/pdb/ZMR http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/pubchem-compound/60855 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/pubchem-substance/46508581 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/pharmgkb/PA164740891 http://linked.opendata.cz/resource/drugbank/drug/DB00558/identifier/wikipedia/Zanamivir
http://linked.open...mechanismOfAction	The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others. (en)
http://linked.open...drugbank/packager	Aidarex Pharmacuticals LLC Dispensing Solutions GlaxoSmithKline Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2081356 http://linked.opendata.cz/resource/drugbank/patent/2291994 http://linked.opendata.cz/resource/drugbank/patent/5360817 http://linked.opendata.cz/resource/drugbank/patent/6294572
http://linked.open...outeOfElimination	It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Zanamivir is renally excreted as unchanged drug. (en)
http://linked.open.../drugbank/synonym	ZANAMIVIR (en) Relenza (en) GANA (en) GNA (en) Modified sialic acid (en) ZMR (en) Zanamavir (en) 5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid (en) 4-Guanidino-neu5ac2en (en) 5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid (en) (2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid (en) 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/08-18-28
http://linked.open...nk/proteinBinding	Zanamivir has limited plasma protein binding (<10%). (en)
http://linked.open...ynthesisReference	Manjinder Singh Phull, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Ashwini Amol Sawant, Sanoj Thoppil, "Process for Preparing Zanamivir and Intermediates for Use in the Process." U.S. Patent US20110257418, issued October 20, 2011. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0217195
foaf:page	http://www.drugs.com/cdi/zanamivir.html http://www.rxlist.com/cgi/generic2/zanam.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B476D-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4773-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4772-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B476F-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4770-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4771-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B476B-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4769-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B476C-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4783-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B476A-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Zanamivir
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4779-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B477A-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4774-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4775-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4777-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4776-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4778-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%. (en)
http://linked.open.../affectedOrganism	Influenza A virus (en) Influenza B virus (en)
http://linked.open...casRegistryNumber	139110-80-8 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 2.5 - 10.9 L/h [Following oral inhalation 10 mg] * 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg] * 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg] * 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg] (en)
http://linked.open...gbank/containedIn	Apo-Sulfinpyrazone 200 mg Tablet Norpace CR 100 mg 12 Hour Capsule
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B477F-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4781-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4782-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B477E-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B477D-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4780-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B476E-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B477B-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B477C-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software